158 results
8-K
EX-10.1
ADIL
Adial Pharmaceuticals Inc
9 Dec 21
Adial Announces Cary J. Claiborne, a Renowned Pharmaceutical Executive and Current Board Member, has Joined the Company as Chief Operating Officer
9:29am
of the Board (excluding the Executive), which consent shall not be unreasonably withheld.
3. Compensation and Other Benefits.
3.1. Base Salary. During … benefit plans and programs maintained from time to time for the benefit of the Company’s employees (e.g., medical, dental and disability benefits
8-K
EX-10.1
ADIL
Adial Pharmaceuticals Inc
23 Aug 22
Departure of Directors or Certain Officers
6:02am
by Section 4.2.4, then the Executive shall be entitled to receive the Accrued Benefits and, subject to Section 4.2.4: (i) the Unpaid Prior Year Bonus … and employee benefits from the Company or its Affiliates, other than as set forth in this Section 4.2.3, shall immediately terminate upon the Termination Date
8-K
ADIL
Adial Pharmaceuticals Inc
10 Dec 20
Entry into a Material Definitive Agreement
9:45am
diseases and disorders such as cocaine addiction, infectious disease, inflammation, cancer, asthma, and diabetes.
Potential Benefits of the Acquisition … will not occur or will be delayed, and Adial and Purnovate each may lose some or all of the intended benefits of the Acquisition.
Several of Purnovate’s
8-K
EX-99.1
ADIL
Adial Pharmaceuticals Inc
16 Jul 21
Adial Announces Positive Pre-Clinical Data for its Adenosine Pain Platform
9:20am
also identified other potential physiological benefits, including increased insulin sensitivity, which could result in licensing or partnership … Purnovate’s position in the field of pain management, other unique potential physiological benefits, including increased insulin sensitivity, resulting
S-8
EX-4.1
ADIL
Adial Pharmaceuticals Inc
17 Aug 18
Registration of securities for employees
9:23am
beneficiary designation submitted to the Administrator to receive the benefits specified under the Plan upon such Participant’s death … and distribution to receive such benefits.
“Board of Directors” shall mean the Board of Directors of the Company.
“Capital Stock” means each and every
8-K
EX-99.1
jfij lc6am
10 Dec 20
Entry into a Material Definitive Agreement
9:45am
8-K
EX-1.1
dk3w3x
26 Feb 19
Adial Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering
8:10am
8-K
EX-10.2
ddgdbi3
23 Aug 22
Departure of Directors or Certain Officers
6:02am
8-K/A
EX-99.1
lp7 msyo0g3w
25 Jan 19
Adial Pharmaceuticals Receives $1.2 Million in Proceeds Through the Exercise of Warrants
4:32pm
8-K
EX-99.1
jdd2b6c00x
29 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:47pm
8-K
EX-99.1
wtj9ogwkpjnmypl iqz
23 Aug 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:45am
8-K
EX-99.1
7sw7ps9
24 Jan 19
Adial Pharmaceuticals Receives $1.2 Million in Proceeds Through the Exercise of Warrants
9:59pm
8-K
EX-99.1
pu0ds 4qrp29
31 Aug 21
Adial Pharmaceuticals Exceeds Enrollment Target In Onward™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder
10:39am
8-K
EX-99.1
xnsa8rmp1 7a7j
22 Sep 20
Adial Pharmaceuticals and iRemedy Partner to Sell COVID-19 Antibody Test Kits to U.S. Medical Providers and Commence Sales
9:31am
8-K
EX-99.1
q3fwqb18 pzkamavezk
22 Dec 21
Adial Pharmaceuticals Completes Private Placement of Common Stock at $4.00 Per Share
12:00am
8-K
EX-99.1
oxsrxm
9 Jul 21
Entry into a Material Definitive Agreement
8:00am
8-K
EX-99.1
r7hiuyg93 dd9
28 Sep 20
Adial Pharmaceuticals Files for Expedited Review of AD04 with the FDA
9:52am
8-K
EX-99.1
xh2l39s
15 Mar 21
Adial Announces Management-Led $2,100,000
9:24am